• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study.初级医疗服务提供者对大麻二酚(CBD)的态度、经验和做法以及关于CBD使用的医患沟通障碍:一项定性研究。
PEC Innov. 2022 Apr 28;1:100044. doi: 10.1016/j.pecinn.2022.100044. eCollection 2022 Dec.
2
Differences in Cannabidiol-Related Attitudes and Practice Behaviors Between U.S. Primary Care Physicians Practicing in a Single Health Care System Across States With and Without Marijuana Legalization.美国在有和没有大麻合法化的州的单一医疗体系中,从事初级保健的医生在与大麻素相关的态度和实践行为方面存在差异。
Cannabis Cannabinoid Res. 2024 Aug;9(4):1038-1047. doi: 10.1089/can.2023.0011. Epub 2023 May 23.
3
Primary Care Providers' Use of Genetic Services in the Southeast United States: Barriers, Facilitators, and Strategies.美国东南部初级保健提供者对遗传服务的使用:障碍、促进因素和策略。
J Prim Care Community Health. 2022 Jan-Dec;13:21501319221134752. doi: 10.1177/21501319221134752.
4
5
Primary care provider management of patients with obesity at an integrated health network: A survey of practices, views, and knowledge.综合健康网络中初级保健提供者对肥胖患者的管理:实践、观点和知识调查。
Surg Obes Relat Dis. 2018 Aug;14(8):1149-1154. doi: 10.1016/j.soard.2018.05.002. Epub 2018 Jun 5.
6
Factors for Supporting Primary Care Physician Engagement With Patient Apps for Type 2 Diabetes Self-Management That Link to Primary Care: Interview Study.支持初级保健医生参与与初级保健相关的 2 型糖尿病自我管理患者应用程序的因素:访谈研究。
JMIR Mhealth Uhealth. 2019 Jan 16;7(1):e11885. doi: 10.2196/11885.
7
Enablers and barriers for the provision of community-based HCV treatment: A case study of a real-world practice.为提供基于社区的 HCV 治疗提供的助力因素和障碍:真实世界实践的案例研究。
J Viral Hepat. 2020 May;27(5):484-496. doi: 10.1111/jvh.13259. Epub 2020 Feb 3.
8
Identification of barriers, facilitators and system-based implementation strategies to increase teleophthalmology use for diabetic eye screening in a rural US primary care clinic: a qualitative study.识别障碍、促进因素和基于系统的实施策略,以增加美国农村初级保健诊所中远程眼科检查在糖尿病眼病筛查中的使用:一项定性研究。
BMJ Open. 2019 Feb 18;9(2):e022594. doi: 10.1136/bmjopen-2018-022594.
9
Specialist and primary care physicians' views on barriers to adequate preparation of patients for renal replacement therapy: a qualitative study.专科医生和初级保健医生对患者接受肾脏替代治疗充分准备的障碍的看法:一项定性研究。
BMC Nephrol. 2015 Mar 28;16:37. doi: 10.1186/s12882-015-0020-x.
10
Primary care providers' experiences caring for complex patients in primary care: a qualitative study.初级保健提供者在初级保健中照顾复杂患者的经历:一项定性研究。
BMC Fam Pract. 2016 Mar 22;17:34. doi: 10.1186/s12875-016-0433-z.

引用本文的文献

1
Use and perceptions of Cannabidiol among individuals in treatment for opioid use disorder.阿片类药物使用障碍治疗人群中对大麻二酚的使用和认知。
Harm Reduct J. 2024 Jul 17;21(1):135. doi: 10.1186/s12954-024-01051-5.
2
Knowledge and Attitudes of Cannabidiol in Croatia among Students, Physicians, and Pharmacists.克罗地亚学生、医生和药剂师对大麻二酚的了解与态度
Pharmacy (Basel). 2023 Dec 23;12(1):2. doi: 10.3390/pharmacy12010002.

本文引用的文献

1
Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.全国纤维肌痛患者调查中的大麻二酚产品剂量和决策。
J Pain. 2022 Jan;23(1):45-54. doi: 10.1016/j.jpain.2021.06.007. Epub 2021 Jun 30.
2
Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey.纤维肌痛患者中用大麻二酚替代阿片类药物和止痛药:一项大型在线调查。
J Pain. 2021 Nov;22(11):1418-1428. doi: 10.1016/j.jpain.2021.04.011. Epub 2021 May 13.
3
Cannabidiol as a Treatment for Chronic Pain: A Survey of Patients' Perspectives and Attitudes.大麻二酚作为慢性疼痛的治疗方法:患者观点与态度调查
J Pain Res. 2021 May 5;14:1241-1250. doi: 10.2147/JPR.S278718. eCollection 2021.
4
CBD Use in Children-Miracle, Myth, or Mystery?儿童使用大麻二酚——奇迹、神话还是谜团?
JAMA Pediatr. 2021 Jun 1;175(6):652. doi: 10.1001/jamapediatrics.2021.0367.
5
Communication between healthcare providers and medical cannabis patients regarding referral and medication substitution.医疗服务提供者与医用大麻患者之间关于转诊和药物替代的沟通。
J Cannabis Res. 2021 Jan 24;3(1):2. doi: 10.1186/s42238-021-00058-0.
6
Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.大麻二酚治疗纤维肌痛:一项大型在线调查中药物使用的流行率及其有效性的认知。
J Pain. 2021 May;22(5):556-566. doi: 10.1016/j.jpain.2020.12.001. Epub 2021 Jan 2.
7
Cannabis in Pregnancy and Lactation - A Review.妊娠期和哺乳期使用大麻 - 综述。
Mo Med. 2020 Sep-Oct;117(5):400-405.
8
Medical Fraud, Mislabeling, Contamination: All Common in CBD Products.医疗欺诈、标签错误、污染:这些在大麻二酚(CBD)产品中都很常见。
Mo Med. 2020 Sep-Oct;117(5):394-399.
9
Assessment of caregiver expectations of physician communication in a pediatric setting.评估儿科环境中照护者对医生沟通的期望。
BMC Health Serv Res. 2020 May 11;20(1):408. doi: 10.1186/s12913-020-05262-x.
10
The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence.大麻二酚(CBD)在慢性疼痛管理中的作用:对现有证据的评估。
Curr Pain Headache Rep. 2020 Jan 24;24(2):4. doi: 10.1007/s11916-020-0835-4.

初级医疗服务提供者对大麻二酚(CBD)的态度、经验和做法以及关于CBD使用的医患沟通障碍:一项定性研究。

Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study.

作者信息

Sharma Pravesh, Holland Ashley, Sheikh Taharat, Novy Blake, Oesterle Tyler, Platt Rheanna, Hammond Christopher J

机构信息

Mayo Clinic Health System, 1221 Whipple St., Eau Claire, WI 54703, USA.

Johns Hopkins School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA.

出版信息

PEC Innov. 2022 Apr 28;1:100044. doi: 10.1016/j.pecinn.2022.100044. eCollection 2022 Dec.

DOI:10.1016/j.pecinn.2022.100044
PMID:37213726
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10194378/
Abstract

OBJECTIVES

Federal hemp legalization and ongoing shifts in US marijuana laws have led to increased population-wide use of cannabidiol (CBD) supplements, often without the knowledge of primary healthcare providers (PCPs). Given the potential risks related to CBD use, especially in vulnerable subgroups, improved communication is warranted. This study aimed to examine PCP attitudes, experiences, and practice behaviors related to CBD and provider-reported barriers to communication with patients about CBD use.

METHODS

Fourteen PCPs were recruited and participated in semi-structured interviews. Transcripts were digitally analyzed using inductive thematic analysis.

RESULTS

Analyses identified that most PCPs had neutral views about CBD use by their patients. The study found that discussions about CBD use were initiated by patients. Most PCPs cited lack of time, discomfort, low-quality evidence, and low prioritization as reasons for not discussing CBD with patients.

CONCLUSION

PCPs rarely screen for or discuss CBD use with their patients and most of them had neutral views about CBD use by their patients. A number of barriers exist to open dialogue about CBD.

INNOVATION

Our study is the first in-depth report on PCP attitudes, experiences, and practice behaviors related to CBD. The findings of our study have the potential to significantly impact future PCP practice behaviors. These results can inform healthcare system policies around screening for CBD use and PCP communication training. In doing so, these efforts may mitigate risk and optimize benefits related to the expanding CBD market.

摘要

目标

联邦层面大麻合法化以及美国大麻法律的持续变化导致全人群对大麻二酚(CBD)补充剂的使用增加,而初级医疗保健提供者(PCP)往往对此并不知情。鉴于CBD使用存在潜在风险,尤其是在易受影响的亚组中,改善沟通很有必要。本研究旨在调查PCP对CBD的态度、经历和实践行为,以及提供者报告的在与患者沟通CBD使用方面的障碍。

方法

招募了14名PCP并参与半结构化访谈。使用归纳主题分析法对访谈记录进行数字化分析。

结果

分析发现,大多数PCP对患者使用CBD持中立态度。研究发现,关于CBD使用的讨论是由患者发起的。大多数PCP将时间不足、不适感、证据质量低和优先级低作为不与患者讨论CBD的原因。

结论

PCP很少对患者使用CBD进行筛查或讨论,且大多数对患者使用CBD持中立态度。在关于CBD的开放对话方面存在一些障碍。

创新点

我们的研究是关于PCP对CBD的态度、经历和实践行为的首份深入报告。我们研究的结果有可能显著影响未来PCP的实践行为。这些结果可为围绕筛查CBD使用和PCP沟通培训的医疗系统政策提供参考。这样做,这些努力可能会降低与不断扩大CBD市场相关的风险并优化益处。